Salmeterol 50 μg
Sponsors
Novartis Pharmaceuticals, Novartis
Conditions
AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)
Phase 3
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
CompletedNCT00529529
Start: 2007-09-30End: 2008-08-31Updated: 2011-08-29
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
CompletedNCT00567996
Start: 2007-11-30Updated: 2011-08-18
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00622635
Start: 2008-01-31End: 2008-07-31Updated: 2011-08-18
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01089127
Start: 2010-03-31End: 2010-07-31Updated: 2011-08-19